SCHEMBL4963137

SCHEMBL4963137

COC(=O)N1CCN(c2ccc(C3(C(=O)NC4CCC(O)CC4)CC3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 5/20 0.48
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.44
GFER P55789 1/20 0.44
CYP3A4 P08684 6/20 0.44
CYP2C19 P33261 4/20 0.44
MAPK1 P28482 3/20 0.44
MEN1 O00255 2/20 0.44
HIF1A Q16665 3/20 0.42
SYK P43405 1/20 0.41
USP2 O75604 3/20 0.40
HSD17B10 Q99714 3/20 0.40
CYP1A2 P05177 3/20 0.40
PDK2 Q15119 1/20 0.40
CYP2C9 P11712 2/20 0.40
ALOX15 P16050 1/20 0.40
F10 P00742 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4963132 1.00 L3MBTL1 (0.49) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4964826 0.91 MAPT (0.51) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4964821 0.91 MAPT (0.51) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4963897 0.86 RET (0.43) ALDH1A1SMN1; SMN2CYP3A4LMNA
SCHEMBL4964952 0.84 PDK2 (0.45) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4964877 0.84 PDK2 (0.45) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL349977 0.76 HSD11B1 (0.63) L3MBTL1MAPTALDH1A1KMT2ACYP3A4
SCHEMBL4963030 0.76 PDK2 (0.46) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4963551 0.76 PDK2 (0.46) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL350196 0.75 L3MBTL1 (0.56) L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 L3MBTL1 4602/4885MAPT 3691/4885ALDH1A1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.